[ad_1]
Wongkittichote, P., Ah Mew, N. & Chapman, K. A. Propionyl-CoA carboxylase: a review. Mol. Genet. Metab. 122, 145–152 (2017).
Ando, T., Rasmussen, K., Nyhan, W. L. & Hull, D. 3-hydroxypropionate: significance of beta-oxidation of propionate in patients with propionic acidemia and methylmalonic acidemia. Proc. Natl Acad. Sci. USA 69, 2807–2811 (1972).
Ando, T., Rasmussen, K., Wright, J. M. & Nyhan, W. L. Isolation and identification of methylcitrate, a major metabolic product of propionate in patients with propionic acidemia. J. Biol. Chem. 247, 2200–2204 (1972).
Baumgartner, M. R. et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J. Rare Dis. 9, 130 (2014).
Shchelochkov, O. A., Carrillo, N. & Venditti, C. Propionic acidemia. In GeneReviews (eds Adam, M. P. et al.) (Univ. Washington, 1993).
Fraser, J. L. & Venditti, C. P. Methylmalonic and propionic acidemias: clinical management update. Curr. Opin. Pediatr. 28, 682–693 (2016).
Haijes, H. A., Jans, J. J. M., Tas, S. Y., Verhoeven-Duif, N. M. & van Hasselt, P. M. Pathophysiology of propionic and methylmalonic acidemias. Part 1: complications. J. Inherit. Metab. Dis. 42, 730–744 (2019).
Forny, P. et al. Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: first revision. J. Inherit. Metab. Dis. 44, 566–592 (2021).
Vockley, J. et al. Challenges and strategies for clinical trials in propionic and methylmalonic acidemias. Mol. Genet. Metab. 139, 107612 (2023).
Jiang, L. et al. Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia. Nat. Commun. 11, 5339 (2020).
Zabaleta, N., Torella, L., Weber, N. D. & Gonzalez-Aseguinolaza, G. mRNA and gene editing: late breaking therapies in liver diseases. Hepatology 76, 869–887 (2022).
Szebeni, J., Simberg, D., Gonzalez-Fernandez, A., Barenholz, Y. & Dobrovolskaia, M. A. Roadmap and strategy for overcoming infusion reactions to nanomedicines. Nat. Nanotechnol. 13, 1100–1108 (2018).
Diaz-Manera, J. et al. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurol. 20, 1012–1026 (2021).
El-Gharbawy, A. H. et al. An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions. Mol. Genet. Metab. 104, 118–122 (2011).
Yap, S., Vara, R. & Morais, A. Post-transplantation outcomes in patients with PA or MMA: a review of the literature. Adv. Ther. 37, 1866–1896 (2020).
Kremsner, P. G. et al. Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: a phase 1 randomized clinical trial. Wien. Klin. Wochenschr. 133, 931–941 (2021).
Lawitz, E. J. et al. BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial. Hepatology 75, 912–923 (2022).
Zhang, X. et al. Patisiran pharmacokinetics, pharmacodynamics, and exposure–response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin-mediated (hATTR) amyloidosis. J. Clin. Pharmacol. 60, 37–49 (2020).
An, D. et al. Systemic messenger RNA therapy as a treatment for methylmalonic acidemia. Cell Rep. 21, 3548–3558 (2017).
Sampson, H. A. et al. Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J. Allergy Clin. Immunol. 117, 391–397 (2006).
Manivannan, V., Decker, W. W., Stead, L. G., Li, J. T. & Campbell, R. L. Visual representation of National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis. Int. J. Emerg. Med. 2, 3–5 (2009).
Mao, X. et al. Ultrasensitive electrochemical detection of mRNA using branched DNA amplifiers. Electrochem. Commun. 10, 1847–1850 (2008).
[ad_2]
Source link
